Skip to content

Rapport Therapeutics

US · RAPP #2970 by market cap Listed 2024
30.86 -0.29 -0.93%
Live - 5344 symbols - heartbeat 463s ago · 2026-10-08 07:00
Pre-market 31.71 +2.75%
After-hours 30.86 0.00%
Overnight 30.86 0.00%
Market cap
1.48B
P/B
3.50
EPS
-2.86
Reader sentiment Are you bullish or bearish on RAPP?

Anonymous reader poll. Unscientific, not investment advice.

About Rapport Therapeutics

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Founded
2022
CEO
Mr. Abraham N. Ceesay, M.B.A.
Employees
84
Headquarters
Boston, Massachusetts, United States of America
Fiscal year end
12-31
Website
rapportrx.com

Company profile

Exchange
US
Symbol
RAPP
Market-cap rank
#2970
Listing date
2024-06-07
Market cap
1.48B
Float cap
937.95M
Shares out
47.98M
Float shares
30.39M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:02 · For reference only, not investment advice and not tailored to your situation.